Wealthfront Advisers LLC Invests $422,000 in Astrazeneca Plc $AZN

Wealthfront Advisers LLC purchased a new position in shares of Astrazeneca Plc (NYSE:AZN) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 4,586 shares of the company’s stock, valued at approximately $422,000.

Several other large investors also recently modified their holdings of AZN. Binnacle Investments Inc grew its stake in Astrazeneca by 21.8% in the 3rd quarter. Binnacle Investments Inc now owns 660 shares of the company’s stock valued at $51,000 after buying an additional 118 shares in the last quarter. 44 Wealth Management LLC grew its stake in Astrazeneca by 0.7% in the 3rd quarter. 44 Wealth Management LLC now owns 16,722 shares of the company’s stock valued at $1,283,000 after buying an additional 124 shares in the last quarter. CoreCap Advisors LLC grew its stake in Astrazeneca by 30.6% in the 3rd quarter. CoreCap Advisors LLC now owns 534 shares of the company’s stock valued at $41,000 after buying an additional 125 shares in the last quarter. WPG Advisers LLC grew its stake in Astrazeneca by 6.2% in the 4th quarter. WPG Advisers LLC now owns 2,177 shares of the company’s stock valued at $200,000 after buying an additional 128 shares in the last quarter. Finally, Traub Capital Management LLC grew its position in shares of Astrazeneca by 3.3% during the 3rd quarter. Traub Capital Management LLC now owns 4,115 shares of the company’s stock valued at $316,000 after purchasing an additional 130 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on AZN. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Astrazeneca in a research report on Thursday, April 30th. Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a research report on Saturday. DZ Bank upgraded shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. TD Cowen restated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. Finally, Barclays upgraded shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Twelve investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Astrazeneca has an average rating of “Moderate Buy” and a consensus price target of $205.33.

Astrazeneca Stock Performance

NYSE AZN opened at $183.27 on Tuesday. Astrazeneca Plc has a 52-week low of $132.32 and a 52-week high of $212.71. The company has a fifty day moving average of $196.02 and a 200-day moving average of $180.36. The company has a market capitalization of $284.24 billion, a P/E ratio of 27.52, a P/E/G ratio of 1.52 and a beta of 0.26. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91.

Astrazeneca (NYSE:AZN) last announced its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The company had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.93 billion. As a group, equities research analysts predict that Astrazeneca Plc will post 10.26 EPS for the current fiscal year.

Astrazeneca Announces Dividend

The business also recently announced a dividend, which was paid on Monday, March 23rd. Investors of record on Friday, February 20th were given a $1.595 dividend. The ex-dividend date was Friday, February 20th. This represents a yield of 156.0%. Astrazeneca’s payout ratio is 73.43%.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.